EDIT Jan 2026 15.000 call
| Previous close | 0.6300 |
| Open | 0.7000 |
| Bid | 0.5500 |
| Ask | 0.6500 |
| Strike | 15.00 |
| Expiry date | 2026-01-16 |
| Day's range | 0.5300 - 0.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 642 |
ZacksEditas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of -20.63% and 90.26%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireEditas Medicine Announces First Quarter 2024 Results and Business Updates
Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 1/2/3 RUBY clinical trial of reni-cel for severe sickle cell disease On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel for transfusion-dependent beta-thalassemia in mid-2024 and additional updates by year-end 2024 Presenting pre-clinical data at ASGCT on in vivo capabilities to support development of transformative in vivo gene editing medicines
Simply Wall St.Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 71%
Key Insights Significantly high institutional ownership implies Editas Medicine's stock price is sensitive to their...
